🇺🇸 FDA
Pipeline program

Eplontersen

ION-682884-CS2

Phase 3 small_molecule active

Quick answer

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) is a Phase 3 program (small_molecule) at IONIS PHARMACEUTICALS INC with 2 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials